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Prognostic factors have a major role in modern oncology and represent the basis for planning the oncology therapy. Advances in molecular oncology and different researcher in oncogenesis in the BC allow detection of genes or proteins with different mechanisms of action, resulting in the appearance of tumor and metastases. The most explored is Her2/neu gene with tyrosin kinase activity which participates in the cell cycle proliferation, progression, apoptosis and survival.
The aim of the study is to determine the expression of the Her 2/neu protein and its prognostic and predictive value in the patients with early breast cancer. The study has a combined retrospective-prospective approach and consists of 200 patients with EBC in the period from 01.01.2007-30.06.2008 year and the patients were operated and diagnosed with IHH expression of the Her 2/neu, Ki67, p53, and the status of ER and PR. According to the expression of Her2/neu protein the patients were dividend in two groups: Her2-and Her2+ and the results were compared between the groups. Her2+ group is randomized in the 3 subgroups:
1. 33 patients after completion of adjuvant HT are applied target therapy with Tr (AC+T→Tr) This study showed that Her2 /neu protein is on independent prognostic factor in the patients with EBC, and indicates aggressive disease, rapid progression and poor prognosis. Aim: The aim of this survey shall be defined the impact of metabolic syndrome on the occurrence of CVD in postmenopausal women and through the evaluation of the results to make correlation between the occurrence of CVD in postmenopausal women without metabolic syndrome and postmenopausal women with metabolic syndrome.
Material and methods: in cross-sectional study were included 120 women dividend in 2 groups/ premenopausal/ 30 and postmenopausal/ 90 postmenopausal were dividend in those with (66.67%) and without metabolic syndrome (33.33%). In each patient was taken detailed history into the possible existence of cardiovascular disease. Metabolic syndrome was defined in accordance with the criteria of the APT lll. We were taking the following parameters: physical weight, height, WC, systolic, diastolic blood pressure, BMI, CRP, urea, creatinine, uric acid, HDL, LDL, FSH and TGL Mean (standard diviation) age was 41 ± 6.08 in premenopausal women and 59.69 ± 7.74 in postmenopausal women. We determined that in postmenopausal women metabolic syndrome and its components are markedly increased. For p < 0.001, postmenopausal women have increased BMI, WC, CRP, and physical weight. For Z = -2:51, p < 0.05 (p = 0.01) postmenopausal women shall have value for the TGL, HDL, LDL. In premenopausal women 0.19 (OR = 0.19/ ± 95%, CI: 0.04, < OR < 0.84) risk for the presence of coronary heart disease is less and that is significant. In postmenopausal women with metabolic syndrome (66.67%) worsening of the metabolic profile is increased. For p < 0.001 these women shall have high HDL, LDL, CRP, TGL, cholesterol, glucose and WC. In postmenopausal women with metabolic syndrome (OR = 5.21/ ± 95%, CI: 1.42 < OR < 19.18) risk for the presence of coronary disease is higher, than in postmenopausal women, without metabolic syndrome (33.33%), and that is significant.
Conclusion:
In postmenopause we have worsening of the metabolic profile and increased CVD. Aim: Recent studies suggested a role of brain-derived neurotrophic factor (BDNF) in depression. While BDNF levels are lower in depressed patients, antidepressant treatment increases serum BDNF levels of depressed patients. This study aims to test the serum BDNF levels in depressed subjects who have exacerbated depressive symptomatology and to compare them with the serum BDNF levels of healthy control subjects; to test the effect of antidepressant treatment on serum BDNF levels in patients with depressive disorder and to explore the possibility of using serum BDNF levels as a biological marker for depressive disorder.
Methods: Thirty patients (14 women, 16 men) diagnosed with depressive episode according ICD-10 were included in the study. 23 patients had their first episode and were drug -naive; the other 7 patients were drug -free for at least 4 weeks. The severity of depression was assessed with Hamilton Depression Rating Scale (HDRS). The control group consisted of 30 age-and sex-matched subject without any psychiatric disorder. Blood samples were collected at the baseline and after achieved remission (HDRS decrease of minimum 50%).
Results: Before antidepressant treatment the mean serum BDNF level was 12.51 ± 6.17 ng/ml and the mean HDRS score was 28.4 ± 3.65. Serum BDNF levels of the depressed patients were significantly lowers than in the control group (26.89 ± 9.67 ng /ml). At the end of the study, the mean serum BDNF level was 23.51 ± 10.76 ng/ml whereas the mean HDRS score was 7.47 ± 3.18. From the baseline to the remission after 8.07 weeks of treatment, the increase in serum BDNF level and the decrease in HDRS score were statistically significant, respectively. When we compared the serum BDNF levels of depressed patients at remission with levels of the controls, there was no statistically significant difference.
Our study suggests that low BDNF levels may play a pivotal role in the pathophysiology of depressive disorder and the antidepressants may increase BDNF in depressed patients, which may be considered as a nonspecific peripheral marker of depression. Subject: Drug addiction is considered as one of the biggest problems of our time. Production, transport and drug abuse, mostly heroine is at constant increase in Republic of Macedonia as in the world. Practice of the treatment of heroine addicts with buprenorfin is increasingly advisable in the world proportions compared to the treatment with methadone. The aim of the research conducted within the frame of this master thesis is to compare the experiences from the therapeutic approach with buprenofin and methadone in heroine addiction.
Materials and methods:
The research represents descriptive and analytical (case control) study conducted in the period of 2011 on the University Clinic for toxicology and Center for Addictions Kisela Voda in Skopje. The study covered total number of 140 heroine addicts divided in two groups of 70 examinees who minimum 3 months before the start of the research have been voluntarily enrolled in the maintenance treatment with buprenorfil (research/inquiry group) and methadone (controlled group). Both groups were followed for: (1) maintenance dose: (2) the effect of duration of the heroine addiction on the amount of the maintenance dose: (3) the effect of the average daily dose of abused heroine over the amount of the maintenance dose: (4) advantages and disadvantages of the therapeutic treatment with buprenorfin and methadone in heroine addiction. Sample of examinees is random. In both groups the examinees were selected in accordance with previously determined inclusive and exclusive criteria and were paired upon all characteristic that can affect the aims if the research.
Results:
In regards to the average time of heroine abuse, there is a significant difference of two years (ttest < 0.05) between research/inquiry group (5.9 ± 2.3) and controlled group (7.8 ± 2.4). The daily dose of abused heroine at the largest part of examinees of both groups, 47.1% vs 50% , is 0.5 gr. Fifty percent of the addicts of the subjected to the buprenorfin treatment and methadone and of methadone 43.3 ± 16.9 mg. After seven days, buprenorfin maintenance dose in the research/inquiry group is 10.8 ± 4.8 mg, and methadone maintenance dose in the controlled group is 75.3 ± 23.8 mg. Half of the examinees of both, the research/inquiry group and the controlled group, received maximum dose of buprenorfin > 12 mg i.e. maximum dose of dose of methadone > 107.5 mg.
The results have shown that there is a positive and direct correlation between the daily dose of abused heroine and the maintenance buprenorfin dose (R = 0.74, p < 0.05) i.e. methadone dose (R = 0.65, p < 0.05). The most often psychiatric disorder in the both groups is personality disorder, in 25.7% vs 34.3% and the rarest is affective disorder, in 1.43% of the examinees of the controlled group. There is no significant difference in the cases of occurrence of depressive disorder between the examinees of the both groups (Yates corrected = 0.39, df = 1, p = 0.53).
Heroine abuse has been registered at 28.6% o the examinees subjected to buprenorfin treatment and at 47.1% of those subjected to methadone treatment. Consequently the examinees on buprenorfin and methadone treatment most often abused cannabis (48.6%) and benzodiazepines (87.1%). Heroine addicts subjected to buprenorfin therapy significantly less abuse cocaine compared to addicts subjected to methadone treatment (Yates chi-square = 8.77, df = 1, p = 0.003).
At the beginning of the treatment the withdrawal symptoms are more frequent during the therapy with burenorfin in comparison to methadone. However, the difference is insignificant in all analyzed abstention syndromes (yawning, nose running, pieloerection, eyes tearing, tremor, myrdiasis, feeling hot and cold waves, muscle cramps, discomfort, nausea and vomiting, stomach spasm, anxiety and sweating).
Conclusion:
It is necessary that the analysis of the advantages and disadvantages of the therapeutic approach with buprenofin and methadone at heroine addicts stays in the focus of the research interest of national researches. This master study was performed on 122 pts split in 2 groups. First group (n = 58) were pts with EDG and/or echocardiographic signs of right ventricular myocardial infarction (RVMI) and RV dysfunction. Second group (n = 64) were pts without these sins. We used ECG, ECHO and coronary angiography as standard methods for optimal diagnosis. Prognostic values of RVMI and RV systolic dysfunction were determined with monitoring of the occurrence of intrahospital events.
The results showed that the highest risk of the occurrence of RVMI was within the pts with acute myocardial infarction on inferior wall. There was no important correlation between occurrence of RVMI and demographic data, anthropometric measurements, risk factors and blood pressure values. Patients with RVMI showed significantly higher frequency of RV failure than pts without RVMI. On the other hand pts with RVMI had significantly lower values of echocardiographic parameters of global and regional RV dysfunction. Presence of tricuspid regurgitation was much more frequent within the pts with RVMI. Echocardiographic measurements of pulmonary pressure showed much higher values within the pts with RVMI. Coronary angiography showed significantly higher presence of pathological changes (stenosis ≥ 50-99% or occlusion 100%) on right coronary artery within the pts with RVMI. Stenosis or occlusion of artery is main factor for RVMI. Intrahospital complications occurred in 23% of pts (out of 122 total numbers of pts). 32.8% out of these 23% of total pts had ECG signs of RVMI which was significantly higher presence than with the pts without RVMI. Regarding the intrahospital events the only differences between pts with and without RVMI were in occurrences of atrio-ventricular block significantly increases the risk of RVMI. Patients with RVMI had worse prognosis including shorter cumulative period of time without intrahospital events occurance. As most predictive factors for poor intrahospital prognosis are age (older more than younger), presence of clinical signs and symptoms of RV failure, presence of ECG signs of RVMI, lower value of TAPSE, higher values of right atrial pressure and lack of coronary angiography.
Electrocardiography and echocardiography are the most important methods with high accuracy, sensitivity, specificity for determination of presence of RVMI and RV dysfunction as well as in determination of intarhospital prognosis in patients with RVMI. Treatment of these patients with percutaneous coronary intervention guarantees much better prognosis.
85% of women with signs of preterm delivery had abnormal pH value, which confirms the correlation of the increased vaginal pH with the process of preterm delivery. We also registered positive statistically relationship between vaginal pH value and the results of the microbiological analysis and concerning the microbes isolated, the results showed correlation of the presence of Gardnerellla, as well as for Ureaplasma urealytcum with increased vaginal pH value. The study confirmed the efficacy of the local therapy for local therapy for normalization and maintenance of the vaginal pH value.
